Table 3 Characteristics of industry-sponsored clinical trials by study site income level
Trial characteristic | All trials N = 22,511 | Trials with study sites outside high-income countries, N = 6,085 | Trials with study sites exclusively in high-income countries, N = 16,426 | P value c |
|---|---|---|---|---|
Median study sites, N (IQR) | 3 (1–20) | 25 (4–71) | 1 (1–9) | <0.001 |
Median participants enrolled, N (IQR) | 100 (40–283) | 265 (104–554) | 71 (33–186) | <0.001 |
Double-blinded, N (%) | 13,883 (61.7) | 3,945 (64.8) | 9,938 (61.1) | <0.001 |
Industry as lead funder, N (%) | 18,891 (83.9) | 5,758 (94.6) | 13,133 (80.8) | <0.001 |
Sponsored by one of the 10 largest pharmaceutical companies a N (%) | 5,522 (24.5) | 2,182 (35.9) | 3,340 (20.3) | <0.001 |
Phase 3 or 4, N (%) | 8,877 (39.4) | 3,532 (58.0) | 5,345 (32.9) | <0.001 |
Paediatric b N (%) | 1,236 (5.5) | 537 (8.8) | 699 (4.2) | <0.001 |
Median trial length, months d | 15.2 (7.1–27.4) | 20.3 (12.2–34.5) | 13.2 (6.0–25.3) | <0.05 |
Completed, N (%) e | 11,703/16,296 (71.8) | 3,011/4,392 (68.5) | 8,692/11,904 (73.0) | <0.001 |
With results posted on ClinicalTrials.gov, N (%) f | 3,142/11,703 (26.8) | 1,001/3,011 (33.2) | 2,141/8,692 (24.6) | <0.001 |